Clinical Correlates and Outcomes of Methamphetamine‐Associated Cardiovascular Diseases in Hospitalized Patients in California
Background Methamphetamine misuse affects 27 million people worldwide and is associated with cardiovascular disease (CVD); however, risk factors for CVD among users have not been well studied. Methods and Results We studied hospitalized patients in California, captured by the Healthcare Cost and Uti...
Saved in:
Published in | Journal of the American Heart Association Vol. 11; no. 16; p. e023663 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley
16.08.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 2047-9980 2047-9980 |
DOI | 10.1161/JAHA.121.023663 |
Cover
Abstract | Background Methamphetamine misuse affects 27 million people worldwide and is associated with cardiovascular disease (CVD); however, risk factors for CVD among users have not been well studied. Methods and Results We studied hospitalized patients in California, captured by the Healthcare Cost and Utilization Project database, between 2005 and 2011. We studied the association between methamphetamine use and CVD (pulmonary hypertension, heart failure, stroke, and myocardial infarction). Among 20 249 026 persons in the Healthcare Cost and Utilization Project, 66 199 used methamphetamines (median follow-up 4.58 years). Those who used were more likely younger (33 years versus 45 years), male (63.3% versus 44.4%), smoked, misused alcohol, and had depression and anxiety compared with nonusers. Methamphetamine use was associated with the development of heart failure (hazard ratio [HR], 1.53 [95% CI, 1.45-1.62]) and pulmonary hypertension (HR, 1.42 [95% CI, 1.26-1.60]). Among users, male sex (HR, 1.73 [95% CI, 1.37-2.18]) was associated with myocardial infarction. Chronic kidney disease (HR, 2.38 [95% CI, 1.74-3.25]) and hypertension (HR, 2.26 [95% CI, 2.03-2.51]) were strong risk factors for CVD among users. When compared with nonuse, methamphetamine use was associated with a 32% significant increase in CVD, alcohol abuse with a 28% increase, and cocaine use with a 47% increase in CVD. Conclusions Methamphetamine use has a similar magnitude of risk of CVD compared with alcohol and cocaine. Prevention and treatment could be focused on those with chronic kidney disease, hypertension, and mental health disorders. |
---|---|
AbstractList | Background Methamphetamine misuse affects 27 million people worldwide and is associated with cardiovascular disease (CVD); however, risk factors for CVD among users have not been well studied. Methods and Results We studied hospitalized patients in California, captured by the Healthcare Cost and Utilization Project database, between 2005 and 2011. We studied the association between methamphetamine use and CVD (pulmonary hypertension, heart failure, stroke, and myocardial infarction). Among 20 249 026 persons in the Healthcare Cost and Utilization Project, 66 199 used methamphetamines (median follow‐up 4.58 years). Those who used were more likely younger (33 years versus 45 years), male (63.3% versus 44.4%), smoked, misused alcohol, and had depression and anxiety compared with nonusers. Methamphetamine use was associated with the development of heart failure (hazard ratio [HR], 1.53 [95% CI, 1.45–1.62]) and pulmonary hypertension (HR, 1.42 [95% CI, 1.26–1.60]). Among users, male sex (HR, 1.73 [95% CI, 1.37–2.18]) was associated with myocardial infarction. Chronic kidney disease (HR, 2.38 [95% CI, 1.74–3.25]) and hypertension (HR, 2.26 [95% CI, 2.03–2.51]) were strong risk factors for CVD among users. When compared with nonuse, methamphetamine use was associated with a 32% significant increase in CVD, alcohol abuse with a 28% increase, and cocaine use with a 47% increase in CVD. Conclusions Methamphetamine use has a similar magnitude of risk of CVD compared with alcohol and cocaine. Prevention and treatment could be focused on those with chronic kidney disease, hypertension, and mental health disorders. Background Methamphetamine misuse affects 27 million people worldwide and is associated with cardiovascular disease (CVD); however, risk factors for CVD among users have not been well studied. Methods and Results We studied hospitalized patients in California, captured by the Healthcare Cost and Utilization Project database, between 2005 and 2011. We studied the association between methamphetamine use and CVD (pulmonary hypertension, heart failure, stroke, and myocardial infarction). Among 20 249 026 persons in the Healthcare Cost and Utilization Project, 66 199 used methamphetamines (median follow-up 4.58 years). Those who used were more likely younger (33 years versus 45 years), male (63.3% versus 44.4%), smoked, misused alcohol, and had depression and anxiety compared with nonusers. Methamphetamine use was associated with the development of heart failure (hazard ratio [HR], 1.53 [95% CI, 1.45-1.62]) and pulmonary hypertension (HR, 1.42 [95% CI, 1.26-1.60]). Among users, male sex (HR, 1.73 [95% CI, 1.37-2.18]) was associated with myocardial infarction. Chronic kidney disease (HR, 2.38 [95% CI, 1.74-3.25]) and hypertension (HR, 2.26 [95% CI, 2.03-2.51]) were strong risk factors for CVD among users. When compared with nonuse, methamphetamine use was associated with a 32% significant increase in CVD, alcohol abuse with a 28% increase, and cocaine use with a 47% increase in CVD. Conclusions Methamphetamine use has a similar magnitude of risk of CVD compared with alcohol and cocaine. Prevention and treatment could be focused on those with chronic kidney disease, hypertension, and mental health disorders.Background Methamphetamine misuse affects 27 million people worldwide and is associated with cardiovascular disease (CVD); however, risk factors for CVD among users have not been well studied. Methods and Results We studied hospitalized patients in California, captured by the Healthcare Cost and Utilization Project database, between 2005 and 2011. We studied the association between methamphetamine use and CVD (pulmonary hypertension, heart failure, stroke, and myocardial infarction). Among 20 249 026 persons in the Healthcare Cost and Utilization Project, 66 199 used methamphetamines (median follow-up 4.58 years). Those who used were more likely younger (33 years versus 45 years), male (63.3% versus 44.4%), smoked, misused alcohol, and had depression and anxiety compared with nonusers. Methamphetamine use was associated with the development of heart failure (hazard ratio [HR], 1.53 [95% CI, 1.45-1.62]) and pulmonary hypertension (HR, 1.42 [95% CI, 1.26-1.60]). Among users, male sex (HR, 1.73 [95% CI, 1.37-2.18]) was associated with myocardial infarction. Chronic kidney disease (HR, 2.38 [95% CI, 1.74-3.25]) and hypertension (HR, 2.26 [95% CI, 2.03-2.51]) were strong risk factors for CVD among users. When compared with nonuse, methamphetamine use was associated with a 32% significant increase in CVD, alcohol abuse with a 28% increase, and cocaine use with a 47% increase in CVD. Conclusions Methamphetamine use has a similar magnitude of risk of CVD compared with alcohol and cocaine. Prevention and treatment could be focused on those with chronic kidney disease, hypertension, and mental health disorders. |
Author | Parikh, Nisha I. Tseng, Zian Nah, Gregory Marcus, Gregory M. Curran, Lara Crawford, Michael H. |
Author_xml | – sequence: 1 givenname: Lara surname: Curran fullname: Curran, Lara organization: Department of Medicine Division of Cardiology, University of California San Francisco San Francisco CA – sequence: 2 givenname: Gregory orcidid: 0000-0002-3543-519X surname: Nah fullname: Nah, Gregory organization: Department of Medicine Division of Cardiology, University of California San Francisco San Francisco CA – sequence: 3 givenname: Gregory M. orcidid: 0000-0001-5197-7696 surname: Marcus fullname: Marcus, Gregory M. organization: Department of Medicine Division of Cardiology, University of California San Francisco San Francisco CA – sequence: 4 givenname: Zian surname: Tseng fullname: Tseng, Zian organization: Department of Medicine Division of Cardiology, University of California San Francisco San Francisco CA – sequence: 5 givenname: Michael H. orcidid: 0000-0001-7103-2278 surname: Crawford fullname: Crawford, Michael H. organization: Department of Medicine Division of Cardiology, University of California San Francisco San Francisco CA – sequence: 6 givenname: Nisha I. orcidid: 0000-0002-4531-9897 surname: Parikh fullname: Parikh, Nisha I. organization: Department of Medicine Division of Cardiology, University of California San Francisco San Francisco CA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35912709$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU1vFSEUhompsbV27c7M0s29BYYZhuXN-HFraupC1-TwMZaGgSswTXSjP8Hf6C-R21sbYyILOBye9yU571N0FGKwCD0neE1IT87fbbabNaFkjWnb9-0jdEIx4yshBnz0V32MznK-wXX1lLedeIKO604ox-IEfR-9C06Db8aYkvVQbG4gmOZqKTrO9RKn5r0t1zDvrm2B2QX768fPTc5RuwqbZoRkXLyFrBcPqXnlsoVcdS4025h3roB33yr3AYqzodw9jLU3xRQcPEOPJ_DZnt2fp-jTm9cfx-3q8urtxbi5XGmGWVlREJRrqs1klTaYTbxXWAxdC4ITwhVXPTVGMzoobGmnbUewNpq0SlM29Lg9RRcHXxPhRu6SmyF9lRGcvGvE9FlCKk57KzUl3AjSKc4Y6ziHiVAFDFpOMJnI3uvlwWuX4pfF5iJnl7X1HoKNS5a0F3W2rKVDRV_co4uarXn4-E8AFTg_ADrFnJOdHhCC5T5luU9Z1pTlIeWq6P5R6Drj4mIoCZz_r-43frysTA |
CitedBy_id | crossref_primary_10_1186_s12916_024_03646_y crossref_primary_10_1016_j_bbadis_2024_167284 crossref_primary_10_1177_10815589251327524 crossref_primary_10_1007_s40429_024_00610_x crossref_primary_10_1080_02699052_2025_2469705 crossref_primary_10_5812_ijhrba_147435 crossref_primary_10_1016_j_jacadv_2024_100840 crossref_primary_10_1164_rccm_202302_0327SO crossref_primary_10_1136_bmjopen_2024_095348 crossref_primary_10_1080_15563650_2023_2191819 crossref_primary_10_1016_j_dadr_2024_100219 crossref_primary_10_1093_ehjdh_ztae094 crossref_primary_10_1186_s12888_024_06018_1 |
Cites_doi | 10.1002/clc.20367 10.1001/jamanetworkopen.2018.3758 10.1016/j.cardfail.2019.10.002 10.1081/clt-120026521 10.1016/j.jchf.2018.01.004 10.1016/j.amjmed.2006.01.024 10.1164/rccm.201705-0943OC 10.1161/ATVBAHA.119.312461 10.1002/clc.4960121211 10.1016/j.jchf.2017.10.006 10.1016/j.ajem.2018.01.001 10.1378/chest.130.6.1657 10.1111/j.1360-0443.2008.02231.x 10.1093/cvr/cvq043 10.1016/j.drugalcdep.2012.11.016 10.1016/S0167-5273(08)70628-4 10.1016/j.amjcard.2019.09.030 10.3390/ijerph182212259 |
ContentType | Journal Article |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
DOI | 10.1161/JAHA.121.023663 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ (Directory of Open Access Journals) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2047-9980 |
ExternalDocumentID | oai_doaj_org_article_c217d915b7444577af12ba4a37101f10 35912709 10_1161_JAHA_121_023663 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL126555 |
GroupedDBID | 0R~ 1OC 24P 53G 5VS 8-1 AAYXX AAZKR ACCMX ACGFO ACXQS ADBBV ADKYN ADZMN AEGXH AENEX AIAGR ALAGY ALMA_UNASSIGNED_HOLDINGS AOIJS AVUZU BAWUL BCNDV CITATION DIK EBS EMOBN GODZA GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 RAH RNS RPM AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 WIN |
ID | FETCH-LOGICAL-c404t-2a927c2cdfebcd04f76b09853a97117b7b62ddc428b0e25ce510cdc13bc248603 |
IEDL.DBID | M48 |
ISSN | 2047-9980 |
IngestDate | Wed Aug 27 00:31:56 EDT 2025 Fri Sep 05 04:16:09 EDT 2025 Thu Jul 24 02:16:25 EDT 2025 Tue Jul 01 03:15:27 EDT 2025 Thu Apr 24 23:01:47 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Keywords | MINOCA methamphetamine pulmonary hypertension myocardial infarction congestive heart failure myocardial infarction without coronary artery obstruction stroke |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c404t-2a927c2cdfebcd04f76b09853a97117b7b62ddc428b0e25ce510cdc13bc248603 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-7103-2278 0000-0002-3543-519X 0000-0001-5197-7696 0000-0002-4531-9897 |
OpenAccessLink | https://doaj.org/article/c217d915b7444577af12ba4a37101f10 |
PMID | 35912709 |
PQID | 2697094328 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c217d915b7444577af12ba4a37101f10 proquest_miscellaneous_2697094328 pubmed_primary_35912709 crossref_primary_10_1161_JAHA_121_023663 crossref_citationtrail_10_1161_JAHA_121_023663 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-08-16 |
PublicationDateYYYYMMDD | 2022-08-16 |
PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-16 day: 16 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of the American Heart Association |
PublicationTitleAlternate | J Am Heart Assoc |
PublicationYear | 2022 |
Publisher | Wiley |
Publisher_xml | – name: Wiley |
References | e_1_3_1_21_2 e_1_3_1_8_2 e_1_3_1_13_2 e_1_3_1_7_2 e_1_3_1_12_2 e_1_3_1_11_2 e_1_3_1_9_2 e_1_3_1_10_2 e_1_3_1_20_2 e_1_3_1_4_2 e_1_3_1_17_2 e_1_3_1_3_2 e_1_3_1_16_2 e_1_3_1_6_2 e_1_3_1_15_2 e_1_3_1_5_2 e_1_3_1_14_2 e_1_3_1_2_2 e_1_3_1_19_2 e_1_3_1_18_2 |
References_xml | – ident: e_1_3_1_17_2 doi: 10.1002/clc.20367 – ident: e_1_3_1_14_2 doi: 10.1001/jamanetworkopen.2018.3758 – ident: e_1_3_1_20_2 doi: 10.1016/j.cardfail.2019.10.002 – ident: e_1_3_1_18_2 doi: 10.1081/clt-120026521 – ident: e_1_3_1_12_2 – ident: e_1_3_1_5_2 doi: 10.1016/j.jchf.2018.01.004 – ident: e_1_3_1_6_2 doi: 10.1016/j.amjmed.2006.01.024 – ident: e_1_3_1_8_2 doi: 10.1164/rccm.201705-0943OC – ident: e_1_3_1_4_2 doi: 10.1161/ATVBAHA.119.312461 – ident: e_1_3_1_16_2 doi: 10.1002/clc.4960121211 – ident: e_1_3_1_21_2 doi: 10.1016/j.jchf.2017.10.006 – ident: e_1_3_1_19_2 doi: 10.1016/j.ajem.2018.01.001 – ident: e_1_3_1_7_2 doi: 10.1378/chest.130.6.1657 – ident: e_1_3_1_9_2 doi: 10.1111/j.1360-0443.2008.02231.x – ident: e_1_3_1_10_2 doi: 10.1093/cvr/cvq043 – ident: e_1_3_1_3_2 doi: 10.1016/j.drugalcdep.2012.11.016 – ident: e_1_3_1_11_2 doi: 10.1016/S0167-5273(08)70628-4 – ident: e_1_3_1_2_2 – ident: e_1_3_1_15_2 doi: 10.1016/j.amjcard.2019.09.030 – ident: e_1_3_1_13_2 doi: 10.3390/ijerph182212259 |
SSID | ssj0000627359 |
Score | 2.3880253 |
Snippet | Background Methamphetamine misuse affects 27 million people worldwide and is associated with cardiovascular disease (CVD); however, risk factors for CVD among... Background Methamphetamine misuse affects 27 million people worldwide and is associated with cardiovascular disease (CVD); however, risk factors for CVD among... |
SourceID | doaj proquest pubmed crossref |
SourceType | Open Website Aggregation Database Index Database Enrichment Source |
StartPage | e023663 |
SubjectTerms | Cardiovascular Diseases - etiology Cocaine congestive heart failure Heart Failure - complications Humans Hypertension - complications Hypertension, Pulmonary - complications Male methamphetamine Methamphetamine - adverse effects MINOCA myocardial infarction Myocardial Infarction - complications myocardial infarction without coronary artery obstruction pulmonary hypertension Renal Insufficiency, Chronic - complications Risk Factors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV09T-QwELVOFIgG8XksB8hIFDQ5HMex4xIW0AppOQqQ6Cx_CqQli9hscw33E-438ksYx9kFCkRDmcRWLL9x5jnjeYPQQV7BmpGkyoASmYzxIDIDZpIF500oDTAGEhOFh5d8cMMubsvbd6W-4pmwJA-cJu7IAmd2Mi-NYIyVQuiQU6OZLsA15iElVxFJ3m2m0jcY3HIpOy0fYDVHF8eD-OMvKnQWnBcf3FCr1v85xWxdzfkKWu44Ij5OY1tFP3y9hhaHXRR8HT13Yp4j3I-1NUaRLmJdO_xn2oABwcU44KFv7jRA5Rv9AL1e_v2fIeEd7n84hYpPU5Rmgu9rPCskcv8X2l0l1dX2wVsW1wa6OT-77g-yrpBCZhlhTUa1pMJS64I31hEWBDdEgqPWUuS5MMJw6pyFnYghnpbWw0K1zuaFsTQWqSo20UI9rv0WwoABoZKbYHjBBAuVdAUtK2oK6oD9iR76PZtXZTuV8VjsYqTa3QbPVQRCARAqAdFDh_MOj0lg4_OmJxGoebOojN3eAHtRnb2or-ylh_ZnMCtYSTE8oms_nk4U5VLEc5a06qGfCf_5q8CWYohebn_HEH6hJRqTKKKwLt9BC83T1O8CtWnMXmvFr1yT9No priority: 102 providerName: Directory of Open Access Journals |
Title | Clinical Correlates and Outcomes of Methamphetamine‐Associated Cardiovascular Diseases in Hospitalized Patients in California |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35912709 https://www.proquest.com/docview/2697094328 https://doaj.org/article/c217d915b7444577af12ba4a37101f10 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LbtQwFLWgSIhNxZvhURmJBZsU23HseIFQGahGlQZYMFJ3lp-l0pChMxkJ2MAn8I18CdeOZ6pKrcQyiZNYOffmnuvHuQi9oC34jCJtBZTIVlxEWVkwkyr6YGNjgTGQtFF4-kFMZvzouDk-LwdUPuDq0tQu1ZOaLef7389-vAGHf50dXtBXRweTNKaXxDdrCKDX0Q0ISyyZ-LRw_eG3DJE6F09jSZ0A0gxSpH4uecaFKJXF_K9moDkSHd5Gu4VC4oMB8zvoWujuopvTMkl-D_0qWp9zPE6lN-aJTWLTefxx3YN9wcEi4mnovxhAMvTmK9z19_efDVDB4_GFRar43TCJs8KnHd7UGTn9Ce0-DaKs-cL5Jq_7aHb4_vN4UpU6C5XjhPcVM4pJx5yPwTpPeJTCEgVx3ChJqbTSCua9g0TFksAaF8CPnXe0to6lGlb1A7TTLbrwCGHOG8KUsNGKmkseW-Vr1rTM1swDOZQjtL_5rtoVEfJUC2OuczIiqE5AaABCD0CM0MvtDd8G_Y2rm75NQG2bJeHsfGKxPNHFD7WDFMwr2ljJoa9SmkiZNdzUwLRopGSEnm9g1uBoafbEdGGxXmkmlEzLMFk7Qg8H_LevArtKM_jq8f_39gm6xdJOiqSuK56inX65Ds-A3_R2L48L7GXr_QcoIfX3 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Correlates+and+Outcomes+of+Methamphetamine%E2%80%90Associated+Cardiovascular+Diseases+in+Hospitalized+Patients+in+California&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Curran%2C+Lara&rft.au=Nah%2C+Gregory&rft.au=Marcus%2C+Gregory+M.&rft.au=Tseng%2C+Zian&rft.date=2022-08-16&rft.issn=2047-9980&rft.eissn=2047-9980&rft.volume=11&rft.issue=16&rft_id=info:doi/10.1161%2FJAHA.121.023663&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_JAHA_121_023663 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon |